Further characterization of the stimulus properties of 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline.
Richard A Glennon, Richard Young, Jagadeesh B Rangisetty
Pharmacology, Biochemistry, and Behavior May 2002 DOI: 10.1016/s0091-3057(01)00768-7 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical animal study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | TDIQ DOM (+)amphetamine MDMA PMMA TDIQ analogs |
| Dose | DOM 1.0 mg/kg, (+)amphetamine 1.0 mg/kg, MDMA 1.5 mg/kg, TDIQ 5.0 mg/kg |
| Measures | drug discrimination, radioligand binding |
| Key points | TDIQ produces discriminative stimulus effects in rats that do not generalize to amphetamine, DOM, MDMA, or PMMA. Several TDIQ analogs substituted for TDIQ but not for the other phenylalkylamines, and N-methylation abolished TDIQ-like stimulus action. Preliminary binding studies suggest an alpha2-adrenergic mechanism may underlie TDIQ's stimulus effects. |
Abstract
This investigation is based on the premise that conformational restriction of abused phenylalkylamines in a tetrahydroisoquinoline conformation alters their pharmacology in such a manner that their original action is lost and that a new action emerges. TDIQ or 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline, is a conformationally constrained phenylalkylamine that serves as a discriminative stimulus in animals. Although TDIQ bears structural resemblance to phenylalkylamine stimulants (e.g., amphetamine), hallucinogens (e.g., 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane [DOM]), and designer drugs (e.g., N-methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane [MDMA], N-methyl-1-(4-methoxyphenyl)-2-aminopropane [PMMA]), the TDIQ stimulus failed to generalize to (+)amphetamine or MDMA. In the present investigation, further evaluations were made of the stimulus nature of TDIQ. Specifically, the stimulus similarities of TDIQ, PMMA, and DOM were examined. In no case was stimulus generalization (substitution) observed. The results confirm that TDIQ produces stimulus effects distinct from those of the abovementioned phenylalkylamines. We also examined the structure-activity relationships of a series of TDIQ analogs, including several that might be viewed as conformationally restricted (CR) analogs of phenylalkylamine hallucinogens, stimulants, and designer drugs. These agents were examined in rats trained to discriminate either DOM (1.0 mg/kg), (+)amphetamine (1.0 mg/kg), MDMA (1.5 mg/kg), or TDIQ (5.0 mg/kg) from saline vehicle. Whereas we have demonstrated that none of these agents retains their respective phenylalkylamine stimulus actions, several of these agents were found to substitute for TDIQ. N-Methylation abolished TDIQ-stimulus action. These results, coupled with previous findings, imply that TDIQ derivatives represent a novel class of phenylalkylamines analogs with unique stimulus properties. Preliminary radioligand binding studies suggest that an alpha2-adrenergic mechanism might underlie the stimulus effects produced by TDIQ.
Citations in the library
Cited by 3
- Effects of para-methoxyamphetamine (PMA) on agonistic encounters between male mice. Pharmacology, Biochemistry, and Behavior April 2018
- The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse. Journal of Medicinal Chemistry March 15, 2017
- Effect of Some Psychoactive Drugs Used as ‘Legal Highs’ on Brain Neurotransmitters Neurotoxicity Research April 1, 2016
Cites 9
- Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class Journal of Medicinal Chemistry October 1, 1986
- Initial characterization of PMMA as a discriminative stimulus. Pharmacology, Biochemistry, and Behavior 1997
- PMMA-stimulus generalization to the optical isomers of MBDB and 3,4-DMA. Pharmacology, Biochemistry, and Behavior 2001
- 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neuroscience and biobehavioral reviews March 1999
- Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats. Psychopharmacology April 1995
and 4 more in the library